drugset / Trial / NCT06002841

Extracellular Vesicles From Mesenchymal Cells in the Treatment of Acute Respiratory Failure

NCT06002841

RandomizedParallel-groupDouble-blindTreatment

Summary

This is a phase I/II, randomized, double-blind, placebo-controlled clinical trial that will evaluate the safety and potential efficacy of therapy with extracellular vesicles (EVs) obtained from mesenchymal stromal cells (MSCs), patients with moderate to severe acute respiratory distress syndrome due to COVID-19 or other etiology. Participants will be allocated to receive EVs obtained from MSCs or placebo (equal volume of Plasma-Lyte A). Blinding will cover the participants, the multidisciplinary intensive care team and the investigators.

Timeline

Start
2024-02-01
Primary completion
2025-06-01
Completion
2025-06-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Exosome Other / unclassified 25 ml Intravenous